Immunological consequences of selective BRAF inhibitors in malignant melanoma
Open Access
- 1 August 2013
- journal article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 2 (8), e25218
- https://doi.org/10.4161/onci.25218
Abstract
Myeloid-derived suppressor cells (MDSC) potently repress antitumor immunity. The amount of MDSC in the blood of melanoma patients declines in response to vemurafenib, an inhibitor of oncogenic BRAF signaling that abrogates the ability of malignant cells to induce MDSC. This suggests that vemurafenib may be used in combination with various immunotherapeutic agents for the induction of long-lasting tumor regression.Keywords
This publication has 10 references indexed in Scilit:
- Hepatotoxicity with Combination of Vemurafenib and IpilimumabThe New England Journal of Medicine, 2013
- Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsInternational Journal of Cancer, 2013
- Update on the Targeted Therapy of MelanomaCurrent Treatment Options in Oncology, 2013
- Melanoma-induced immunosuppression and its neutralizationSeminars in Cancer Biology, 2012
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic MelanomaClinical Cancer Research, 2012
- Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear CellsPublished by The American Association of Immunologists ,2010
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte FunctionCancer Research, 2010
- Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor VaccineJournal of Clinical Oncology, 2007
- The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cellsThe Journal of Experimental Medicine, 2006
- HUMAN T CELL RESPONSES AGAINST MELANOMAAnnual Review of Immunology, 2006